{"entity":{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","aka":[],"tldr":"Led CheckMate 816, which established neoadjuvant chemo-immunotherapy for resectable lung cancer.","summary":"Patrick M. Forde is Director of the Thoracic Oncology Clinical Research Program at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is known for pioneering neoadjuvant PD-1 blockade in resectable non-small-cell lung cancer, from a 2018 pilot study to leading the CheckMate 816 phase 3 trial that established neoadjuvant nivolumab plus chemotherapy as a standard. His selected papers report neoadjuvant PD-1 blockade in resectable lung cancer and neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. He also leads mesothelioma trials.","asOf":"2026-09-08","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/patrick-forde"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forde%20PM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","mesothelioma"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":["checkmate-816"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Thoracic Oncology Clinical Research Program","institutionId":"johns-hopkins","specialisms":["Neoadjuvant immunotherapy","Lung cancer","Mesothelioma"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/patrick-forde"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forde%20PM%5BAuthor%5D"}],"papers":[{"title":"Neoadjuvant PD-1 blockade in resectable lung cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1716078","doi":"10.1056/NEJMoa1716078"},{"title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2202170","doi":"10.1056/NEJMoa2202170"}]},"route":"/people/patrick-forde/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"}],"trial":[{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/"}],"paper":[{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/"}]}}